Mitsubishi Tanabe Pharma Corporation has presented data that show patients with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 day cycles for 48 weeks experienced significantly less functional loss as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). The data were presented at the 27th International Symposium on ALS/MND in Dublin, Ireland. In the 48-week study, a 24-week double blind placebo controlled phase was followed by a 24-week open label active treatment phase. Data previously presented at the 2016 Annual Meeting of the American Academy of Neurology, showed edaravone met the primary efficacy endpoint of mean change in the ALSFRS-R at 24 weeks. The frequency of serious adverse events was similar to placebo.